GlassScriptPhysician profile
Dong Xiang
NPI 1235332925
$74,485.93
in general payments reported to CMS, 2019-2025
80 companies · $3,937 in 2025
The $3,937 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,871 · 2020: $1,143 · 2021: $3,177 · 2022: $15K · 2023: $33K · 2024: $8,924 · 2025: $3,937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Food and Beverage: $14K · Honoraria: $4,550 · Travel and Lodging: $2,959 · Education: $457 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,791.50 |
| Food and Beverage | $13,704.16 |
| Honoraria | $4,550.00 |
| Travel and Lodging | $2,959.25 |
| Education | $456.70 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $18,545.78 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Seagen INC. | $17,192.32 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Novocure INC. | $6,937.73 | 2020-2023 | |
| Janssen Biotech, INC. | $4,662.67 | 2019-2025 | Imbruvica, Carvykti, Erleada |
| Beigene USA, INC. | $4,266.43 | 2022-2025 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $3,446.90 | 2019-2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $1,361.68 | 2019-2024 | |
| Pfizer INC. | $1,177.59 | 2019-2025 | |
| Incyte Corporation | $1,096.40 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Merck Sharp & Dohme LLC | $1,087.17 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Amgen INC. | $1,056.28 | 2019-2023 | Lumakras, Nplate, Vectibix |
| Glaxosmithkline, LLC. | $914.95 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Astellas Pharma US INC | $793.41 | 2020-2025 | Xospata, Vyloy, Xtandi |
| Celgene Corporation | $761.92 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Genzyme Corporation | $720.26 | 2019-2025 |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $642.52 | 2019-2025 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $612.35 | 2020-2025 | |
| Gilead Sciences, INC. | $597.27 | 2021-2025 | Trodelvy, Vemlidy |
| Sobi, INC | $589.36 | 2021-2025 | |
| Lilly USA, LLC | $546.24 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $489.33 | 2019-2025 | Fruzaqla, Iclusig, Ninlaro |
| Karyopharm Therapeutics INC. | $469.40 | 2022-2025 | Xpovio |
| Exelixis INC. | $449.43 | 2021-2023 | Cabometyx |
| Eisai INC. | $421.98 | 2019-2025 | |
| Abbvie INC. | $421.85 | 2021-2025 | Venclexta, Lupron Depot |
| Pharmacyclics LLC, An Abbvie Company | $385.58 | 2020-2023 | Imbruvica |
| Daiichi Sankyo INC. | $356.80 | 2020-2025 | Enhertu |
| Rigel Pharmaceuticals, INC. | $340.72 | 2019-2023 | Rezlidhia, Tavalisse |
| Puma Biotechnology, INC. | $280.19 | 2019-2025 | |
| Beone Medicines USA, INC. | $278.39 | 2025 | Brukinsa |
| Genentech USA, INC. | $275.18 | 2022-2025 | Tecentriq, Rozlytrek, Alecensa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.50 | 2020-2025 | Gilotrif |
| Adc Therapeutics America, INC. | $247.11 | 2023-2025 | |
| Pharmaessentia USA Corporation | $205.03 | 2022-2025 | Besremi |
| Alexion Pharmaceuticals, INC. | $182.26 | 2019-2025 | Ultomiris |
| Mirati Therapeutics, INC. | $167.12 | 2023 | Krazati |
| Emd Serono, INC. | $158.20 | 2020-2023 | Bavencio |
| Tempus Ai, INC | $149.01 | 2024 | |
| Stemline Therapeutics INC. | $114.41 | 2023-2025 | Orserdu |
| Array Biopharma INC | $110.54 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 | |
| Jazz Pharmaceuticals INC. | $98.86 | 2020-2025 | |
| Ge Healthcare | $97.73 | 2021-2025 | |
| Myovant Sciences INC. | $94.28 | 2021-2022 | |
| Blueprint Medicines Corporation | $88.42 | 2021-2024 | Ayvakit |
| Tersera Therapeutics LLC | $80.16 | 2021-2023 | Zoladex |
| Tolmar Pharmaceuticals, INC. | $76.02 | 2021-2022 | |
| Dova Pharmaceuticals | $63.47 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $61.86 | 2021-2025 | Onivyde, Somatuline Depot |
| Servier Pharmaceuticals LLC | $56.99 | 2025 | |
| Sumitomo Pharma America, INC. | $56.99 | 2023-2024 | Orgovyx |
| Dendreon Pharmaceuticals LLC | $51.75 | 2023 | Provenge |
| Taiho Oncology, INC. | $43.93 | 2022-2025 | |
| Genmab U.S., INC. | $43.59 | 2024 | Epkinly |
| Janssen Scientific Affairs, LLC | $42.47 | 2024-2025 | Balversa, Erleada |
| Agios Pharmaceuticals, INC. | $41.97 | 2020-2025 | Pyrukynd |
| Apellis Pharmaceuticals, INC. | $39.84 | 2022-2023 | Empaveli |
| Morphosys, US INC. | $37.56 | 2021 | |
| Myriad Genetic Laboratories, INC. | $37.30 | 2024 | Myrisk, Precisetumor |
| Legend Biotech USA INC. | $35.80 | 2025 | Carvykti |
| Deciphera Pharmaceuticals INC. | $34.24 | 2022-2023 | Qinlock |
| Geron Corporation | $33.07 | 2025 | Rytelo |
| Eusa Pharma (US) LLC | $31.76 | 2022 | |
| Aveo Pharmaceuticals, INC. | $31.64 | 2025 | |
| Springworks Therapeutics, INC. | $29.25 | 2025 | Ogsiveo |
| Immunogen, INC. | $27.60 | 2023 | Elahere |
| Foundation Medicine, INC. | $25.48 | 2022 | |
| Kyowa Kirin, INC. | $24.34 | 2025 | |
| Organon LLC | $23.59 | 2022 | |
| Novo Nordisk INC | $23.10 | 2021 | |
| Shield Therapeutics INC | $22.77 | 2025 | |
| Progenics Pharmaceuticals, INC. | $20.98 | 2024 | |
| Heron Therapeutics, INC. | $20.43 | 2021 | |
| Coherus Oncology, INC. | $20.04 | 2021 | |
| Recordati_rare_diseases_inc. | $19.81 | 2023 | Sylvant |
| G1 Therapeutics, INC. | $17.60 | 2023 | Cosela |
| Mylan Institutional INC. | $16.47 | 2020 | |
| Optos, INC. | $14.21 | 2021 | |
| Acrotech Biopharma INC. | $13.93 | 2022 | |
| Tolmar, INC. | $13.38 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dong Xiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.